Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00099749

Enrollment

255

Registered

2004-12-20

Start date

2003-11-30

Completion date

Unknown

Last updated

2017-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplantation

Keywords

Kidney, immunosuppression, transplant, rejection

Brief summary

The efficacy and safety of FTY720 is being evaluated in patients who receive a kidney transplant.

Interventions

DRUGFTY 720

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Inclusion criteria

* Male and Female * Between 18 to 65 years old

Exclusion criteria

* Patients in need of multiple organ transplants

Design outcomes

Primary

Measure	Time frame
Biopsy-proven acute rejection (BPAR), graft loss, death and study discontinuation, within 6 months post transplantation.	—

Secondary

Measure	Time frame
Safety/tolerability based on adverse event reporting.	—
BPAR, graft loss, death and study discontinuation, within 6 and 12 months post transplantation.	—
Efficacy parameters between the 3 treatment groups within 6 and 12 months post-transplantation.	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026